Trial Profile

A Dose-Escalation, Open Label Phase I Study to Assess the Safety, Feasibility and Preliminary Efficacy of HA-1H TCR Modified T Cells, MDG1021, in Patients With Relapsed or Persistent Hematologic Malignancies After Allogeneic HSCT With or Without Unmanipulated DLI

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 13 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MDG 1021 (Primary)
Indications Acute myeloid leukaemia; B-cell lymphoma; Chronic myeloid leukaemia; Haematological malignancies; Multiple myeloma; Mycosis fungoides; Myelodysplastic syndromes; Myeloproliferative disorders; Precursor cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma
Focus Adverse reactions
Sponsors MediGene AG

30 Sep 2021 Planned End Date changed from 1 Jan 2024 to 1 Jul 2025.
30 Sep 2021 Status changed from active, no longer recruiting to withdrawn prior to enrolment because Medigene transfered all rights to a new Sponsor.
01 Feb 2021 Status changed from suspended to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com